查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2108388

免疫療法藥物市場分析及預測（至2035年）：類型、產品、技術、應用、製程、最終用戶、給藥途徑、階段

Immunotherapy Drugs Market Analysis and Forecast to 2035: Type, Product, Technology, Application, Process, End User, Mode, Stage
出版日期: | 出版商: Global Insight Services | 英文 350 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

全球免疫療法市場預計將從2025年的2,722億美元成長到2035年的6,942億美元，CAGR為9.8%。隨著癌症發生率的上升和精準醫療的加速應用，該市場持續擴張。世界衛生組織（WHO）預測，2022年全球將有近1,000萬人死於癌症，這將推動先進免疫療法的需求。國際癌症研究機構（IARC）預計，未來幾十年新增癌症病例將顯著增加，這將進一步增強對長期治療的需求。市場評估表明，全球免疫療法市場規模將在2024年超過2000億美元，並在整個預測期內保持兩位數的CAGR，這主要得益於不斷擴大的生物製藥研發管線、法規核准的增加以及醫療保健領域投資的成長。

依類型分類，市場包括單株抗體、查核點抑制劑、細胞激素、癌症疫苗、過繼性細胞療法和溶瘤病毒療法，每種療法都針對不同的免疫機制。單株抗體和查核點抑制劑因其廣泛的應用和在癌症治療領域已證實的臨床療效而佔據市場主導地位。細胞激素在特定治療領域促進免疫活化，而癌症疫苗和溶瘤病毒則提供標靶抗腫瘤反應。過繼性細胞療法，包括基因修飾的免疫細胞，是一個技術先進的領域，其商業化進程持續進行中。持續的創新、不斷擴大的臨床適應症、聯合治療策略以及越來越多的法規核准預計將推動所有治療類別的需求成長。

市場區隔
類型 單株抗體、查核點抑制劑、細胞激素、癌症疫苗、過繼性細胞療法、溶瘤病毒療法、其他
產品 Yervoy、Opdivo、Keytruda、Tecentriq、Imfinzi、Kymriah、Provenge、其他
技術 重組DNA技術、融合瘤技術、基因編輯、奈米技術、其他
用途 癌症、自體免疫疾病、感染疾病、發炎性疾病、其他
過程 體內、體內、其他
最終用戶 醫院、診所、研究機構、生物製藥公司、其他
給藥途徑 靜脈注射、皮下注射、口服、其他
階段 臨床試驗、商業化、其他

產品類別包括治療性疫苗、免疫查核點抑制劑、特異性免疫療法、溶瘤病毒免疫療法和CAR-T細胞療法。免疫查核點抑制劑因其在多種癌症適應症中的廣泛應用而佔據較大的市場佔有率。治療性疫苗正透過個人化醫療方法不斷發展，而非特異性免疫療法在免疫調節中繼續發揮非常重要的作用。溶瘤病毒免疫療法因其選擇性腫瘤破壞和免疫活化作用而備受臨床關注。 CAR-T細胞療法憑藉技術進步、生產規模化以及在骨髓惡性腫瘤方面的不斷擴大而持續成長，支持其在專業醫療機構的長期商業性發展。

區域概覽

北美憑藉其先進的醫療基礎設施、廣泛的生物技術生態系統以及眾多創新製藥公司，在免疫療法市場中保持主導地位。高額的醫療費用支出、廣泛的保險覆蓋範圍以及創新生技藥品的早期應用，共同支撐著這一持續的市場領導地位。該地區受益於積極的臨床試驗、與學術研究的合作以及有利的監管管道，加速了商業化。對精準腫瘤學、細胞療法生產設施和轉化研究的持續投入，進一步強化了產品供應鏈。癌症發生率的上升以及個人化治療方案的日益普及，進一步推動了醫院和專科癌症中心對免疫療法的長期需求。

亞太地區正經歷顯著成長，這主要得益於醫療基礎設施的改善、癌症防治意識的提高以及生物技術研發投入的增加。各國政府正透過扶持措施，支持國內生物製藥生產，擴大癌症治療的可近性，並鼓勵臨床研發。中國、日本、韓國和印度等國正透過科學研究合作和擴大生產能力，增強其免疫療法實力。患者數量的成長、醫療支出的增加以及先進生技藥品的可及性提高，都促進了產品的快速普及。預計在整個預測期內，監管體系的持續現代化以及對細胞和基因治療基礎設施的投資將創造巨大的發展機會。

主要趨勢和促進因素

個人化免疫療法的進展

個人化醫療的進步正推動免疫療法市場顯著成長。個人化免疫療法根據個體的基因譜最佳化治療方案，提高療效並減少副作用。基因組學和生物資訊學領域的技術創新是推動這一趨勢的關鍵，使得靶向癌細胞更加精準。隨著越來越多的製藥公司投資於個人化治療方案，預計市場將迎來此類療法的廣泛應用、患者療效的提升以及免疫療法應用範圍的拓展。

精準腫瘤學推動對先進免疫療法的需求。

全球癌症負擔日益加重以及標靶治療需求的不斷成長是推動市場擴張的主要因素。在多種適應症中，與傳統化療相比，免疫療法藥物能夠提供更持久的臨床療效、更高的存活率並減少對健康組織的傷害。持續的法規核准、不斷擴大的臨床證據、對癌症研究的大量投入以及醫療保健支出的成長，正進一步加速已開發國家和新興國家醫療保健市場對免疫療法的接受度。

目錄

第1章 執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機會
  • 市場限制因素
  • 年複合成長率分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 單株抗體
    • 查核點抑制劑
    • 細胞激素
    • 癌症疫苗
    • 過繼性細胞療法
    • 溶瘤病毒療法
    • 其他
  • 市場規模及預測：依產品分類
    • Yervoy
    • Opdivo
    • Keytruda
    • Tecentriq
    • Imfinzi
    • Kymriah
    • Provenge
    • 其他
  • 市場規模及預測：依技術分類
    • 重組DNA技術
    • 融合瘤技術
    • 基因編輯
    • 奈米科技
    • 其他
  • 市場規模及預測：依應用領域分類
    • 癌症
    • 自體免疫疾病
    • 感染疾病
    • 發炎性疾病
    • 其他
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 診所
    • 研究機構
    • 生物製藥公司
    • 其他
  • 市場規模及預測：依過程分類
    • 體內
    • 體外
    • 其他
  • 市場規模及預測：依給藥途徑分類
    • 靜脈注射
    • 皮下注射
    • 口服
    • 其他
  • 市場規模及預測：依階段分類
    • 臨床試驗
    • 商業化
    • 其他

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲國家
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 其他亞太國家
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲國家

第6章 市場策略

  • 供需差距分析
  • 貿易和物流限制
  • 定價和成本利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 監管概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要公司的策略

第8章 公司簡介

  • Roche
  • Merck
  • Bristol Myers Squibb
  • Novartis
  • Pfizer
  • AstraZeneca
  • Johnson and Johnson
  • Gilead Sciences
  • Amgen
  • Sanofi
  • Eli Lilly and Company
  • AbbVie
  • GlaxoSmithKline
  • Regeneron Pharmaceuticals
  • Biogen
  • Takeda Pharmaceutical
  • Bayer
  • Astellas Pharma
  • Daiichi Sankyo
  • Moderna

第9章 關於我們

簡介目錄
Product Code: GIS24892

The global Immunotherapy Drugs Market is projected to grow from $272.2 billion in 2025 to $694.2 billion by 2035, at a compound annual growth rate (CAGR) of 9.8%. The Immunotherapy Drugs Market continues to expand as cancer incidence increases and precision medicine adoption accelerates. According to the World Health Organization (WHO), cancer caused nearly 10 million deaths globally in 2022, driving demand for advanced immunotherapies. The International Agency for Research on Cancer (IARC) estimates new cancer cases will rise substantially over the coming decades, strengthening long-term treatment demand. Market assessments indicate the global immunotherapy drugs market exceeded USD 200 billion in 2024 and is projected to register a double-digit CAGR through the forecast period, supported by expanding biologics pipelines, increasing regulatory approvals, and growing healthcare investments.

The market by type includes monoclonal antibodies, checkpoint inhibitors, cytokines, cancer vaccines, adoptive cell therapy, and oncolytic virus therapy, each targeting distinct immune mechanisms. Monoclonal antibodies and checkpoint inhibitors dominate due to extensive oncology applications and proven clinical efficacy. Cytokines support immune activation in selected therapeutic areas, while cancer vaccines and oncolytic viruses provide targeted antitumor responses. Adoptive cell therapy, including engineered immune cells, represents a technologically advanced segment with expanding commercialization. Continuous innovation, broader clinical indications, combination treatment strategies, and increasing regulatory approvals are expected to strengthen demand across all therapeutic categories.

Market Segmentation
TypeMonoclonal Antibodies, Checkpoint Inhibitors, Cytokines, Cancer Vaccines, Adoptive Cell Therapy, Oncolytic Virus Therapy, Others
ProductYervoy, Opdivo, Keytruda, Tecentriq, Imfinzi, Kymriah, Provenge, Others
TechnologyRecombinant DNA Technology, Hybridoma Technology, Gene Editing, Nanotechnology, Others
ApplicationCancer, Autoimmune Diseases, Infectious Diseases, Inflammatory Diseases, Others
ProcessIn Vivo, Ex Vivo, Others
End UserHospitals, Clinics, Research Institutes, Biopharmaceutical Companies, Others
ModeIntravenous, Subcutaneous, Oral, Others
StageClinical Trials, Commercialized, Others

The product segment consists of therapeutic vaccines, immune checkpoint inhibitors, non-specific immunotherapies, oncolytic virus immunotherapy, and CAR-T cell therapy. Immune checkpoint inhibitors account for a significant share owing to widespread adoption in multiple cancer indications. Therapeutic vaccines are advancing through personalized medicine approaches, while non-specific immunotherapies remain valuable in immune modulation. Oncolytic virus immunotherapy is gaining clinical interest for selective tumor destruction and immune activation. CAR-T cell therapy continues to expand through technological improvements, manufacturing scalability, and growing approvals for hematological malignancies, supporting long-term commercial growth across specialized healthcare settings.

Geographical Overview

North America maintains a leading position in the Immunotherapy Drugs Market due to its advanced healthcare infrastructure, extensive biotechnology ecosystem, and strong concentration of pharmaceutical innovators. High healthcare expenditure, broad reimbursement coverage, and early adoption of innovative biologics support sustained market leadership. The region benefits from significant clinical trial activity, academic research collaborations, and favorable regulatory pathways that accelerate commercialization. Continuous investment in precision oncology, cell therapy manufacturing facilities, and translational research strengthens product availability. Rising cancer prevalence and increasing adoption of personalized treatment protocols further reinforce long-term demand across hospitals and specialized cancer centers.

Asia-Pacific is experiencing substantial expansion supported by improving healthcare infrastructure, rising cancer awareness, and increasing investments in biotechnology research. Governments are promoting domestic biopharmaceutical manufacturing, expanding oncology treatment access, and encouraging clinical development through supportive policies. Countries including China, Japan, South Korea, and India are strengthening immunotherapy capabilities through research partnerships and manufacturing expansion. Growing patient populations, increasing healthcare expenditure, and greater availability of advanced biologics contribute to accelerating product adoption. Continued regulatory modernization and investments in cell and gene therapy infrastructure are expected to create significant opportunities throughout the forecast period.

Key Trends and Drivers

Advancements in Personalized Immunotherapy:

The immunotherapy drugs market is experiencing significant growth due to advancements in personalized medicine. Personalized immunotherapy involves tailoring treatments based on individual genetic profiles, which enhances efficacy and reduces adverse effects. This trend is driven by technological innovations in genomics and bioinformatics, enabling more precise targeting of cancer cells. As more pharmaceutical companies invest in personalized treatment solutions, the market is expected to see increased adoption of these therapies, offering improved patient outcomes and expanding the scope of immunotherapy applications.

Precision Oncology Fuels Demand for Advanced Immunotherapies:

The increasing global burden of cancer and the growing preference for targeted therapies are primary factors driving market expansion. Immunotherapy drugs offer durable clinical responses, improved survival outcomes, and reduced damage to healthy tissues compared with conventional chemotherapy in several indications. Continuous regulatory approvals, expanding clinical evidence, substantial investments in oncology research, and rising healthcare spending further accelerate adoption across developed and emerging healthcare markets.

Research Scope

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Technology
  • 2.4 Key Market Highlights by Application
  • 2.5 Key Market Highlights by End User
  • 2.6 Key Market Highlights by Process
  • 2.7 Key Market Highlights by Mode
  • 2.8 Key Market Highlights by Stage

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Monoclonal Antibodies
    • 4.1.2 Checkpoint Inhibitors
    • 4.1.3 Cytokines
    • 4.1.4 Cancer Vaccines
    • 4.1.5 Adoptive Cell Therapy
    • 4.1.6 Oncolytic Virus Therapy
    • 4.1.7 Others
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Yervoy
    • 4.2.2 Opdivo
    • 4.2.3 Keytruda
    • 4.2.4 Tecentriq
    • 4.2.5 Imfinzi
    • 4.2.6 Kymriah
    • 4.2.7 Provenge
    • 4.2.8 Others
  • 4.3 Market Size & Forecast by Technology (2020-2035)
    • 4.3.1 Recombinant DNA Technology
    • 4.3.2 Hybridoma Technology
    • 4.3.3 Gene Editing
    • 4.3.4 Nanotechnology
    • 4.3.5 Others
  • 4.4 Market Size & Forecast by Application (2020-2035)
    • 4.4.1 Cancer
    • 4.4.2 Autoimmune Diseases
    • 4.4.3 Infectious Diseases
    • 4.4.4 Inflammatory Diseases
    • 4.4.5 Others
  • 4.5 Market Size & Forecast by End User (2020-2035)
    • 4.5.1 Hospitals
    • 4.5.2 Clinics
    • 4.5.3 Research Institutes
    • 4.5.4 Biopharmaceutical Companies
    • 4.5.5 Others
  • 4.6 Market Size & Forecast by Process (2020-2035)
    • 4.6.1 In Vivo
    • 4.6.2 Ex Vivo
    • 4.6.3 Others
  • 4.7 Market Size & Forecast by Mode (2020-2035)
    • 4.7.1 Intravenous
    • 4.7.2 Subcutaneous
    • 4.7.3 Oral
    • 4.7.4 Others
  • 4.8 Market Size & Forecast by Stage (2020-2035)
    • 4.8.1 Clinical Trials
    • 4.8.2 Commercialized
    • 4.8.3 Others

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Technology
      • 5.2.1.4 Application
      • 5.2.1.5 End User
      • 5.2.1.6 Process
      • 5.2.1.7 Mode
      • 5.2.1.8 Stage
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Technology
      • 5.2.2.4 Application
      • 5.2.2.5 End User
      • 5.2.2.6 Process
      • 5.2.2.7 Mode
      • 5.2.2.8 Stage
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Technology
      • 5.2.3.4 Application
      • 5.2.3.5 End User
      • 5.2.3.6 Process
      • 5.2.3.7 Mode
      • 5.2.3.8 Stage
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Technology
      • 5.3.1.4 Application
      • 5.3.1.5 End User
      • 5.3.1.6 Process
      • 5.3.1.7 Mode
      • 5.3.1.8 Stage
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Technology
      • 5.3.2.4 Application
      • 5.3.2.5 End User
      • 5.3.2.6 Process
      • 5.3.2.7 Mode
      • 5.3.2.8 Stage
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Technology
      • 5.3.3.4 Application
      • 5.3.3.5 End User
      • 5.3.3.6 Process
      • 5.3.3.7 Mode
      • 5.3.3.8 Stage
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Technology
      • 5.4.1.4 Application
      • 5.4.1.5 End User
      • 5.4.1.6 Process
      • 5.4.1.7 Mode
      • 5.4.1.8 Stage
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Technology
      • 5.4.2.4 Application
      • 5.4.2.5 End User
      • 5.4.2.6 Process
      • 5.4.2.7 Mode
      • 5.4.2.8 Stage
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Technology
      • 5.4.3.4 Application
      • 5.4.3.5 End User
      • 5.4.3.6 Process
      • 5.4.3.7 Mode
      • 5.4.3.8 Stage
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Technology
      • 5.4.4.4 Application
      • 5.4.4.5 End User
      • 5.4.4.6 Process
      • 5.4.4.7 Mode
      • 5.4.4.8 Stage
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Technology
      • 5.4.5.4 Application
      • 5.4.5.5 End User
      • 5.4.5.6 Process
      • 5.4.5.7 Mode
      • 5.4.5.8 Stage
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Technology
      • 5.4.6.4 Application
      • 5.4.6.5 End User
      • 5.4.6.6 Process
      • 5.4.6.7 Mode
      • 5.4.6.8 Stage
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Technology
      • 5.4.7.4 Application
      • 5.4.7.5 End User
      • 5.4.7.6 Process
      • 5.4.7.7 Mode
      • 5.4.7.8 Stage
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Technology
      • 5.5.1.4 Application
      • 5.5.1.5 End User
      • 5.5.1.6 Process
      • 5.5.1.7 Mode
      • 5.5.1.8 Stage
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Technology
      • 5.5.2.4 Application
      • 5.5.2.5 End User
      • 5.5.2.6 Process
      • 5.5.2.7 Mode
      • 5.5.2.8 Stage
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Technology
      • 5.5.3.4 Application
      • 5.5.3.5 End User
      • 5.5.3.6 Process
      • 5.5.3.7 Mode
      • 5.5.3.8 Stage
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Technology
      • 5.5.4.4 Application
      • 5.5.4.5 End User
      • 5.5.4.6 Process
      • 5.5.4.7 Mode
      • 5.5.4.8 Stage
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Technology
      • 5.5.5.4 Application
      • 5.5.5.5 End User
      • 5.5.5.6 Process
      • 5.5.5.7 Mode
      • 5.5.5.8 Stage
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Technology
      • 5.5.6.4 Application
      • 5.5.6.5 End User
      • 5.5.6.6 Process
      • 5.5.6.7 Mode
      • 5.5.6.8 Stage
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Technology
      • 5.6.1.4 Application
      • 5.6.1.5 End User
      • 5.6.1.6 Process
      • 5.6.1.7 Mode
      • 5.6.1.8 Stage
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Technology
      • 5.6.2.4 Application
      • 5.6.2.5 End User
      • 5.6.2.6 Process
      • 5.6.2.7 Mode
      • 5.6.2.8 Stage
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Technology
      • 5.6.3.4 Application
      • 5.6.3.5 End User
      • 5.6.3.6 Process
      • 5.6.3.7 Mode
      • 5.6.3.8 Stage
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Technology
      • 5.6.4.4 Application
      • 5.6.4.5 End User
      • 5.6.4.6 Process
      • 5.6.4.7 Mode
      • 5.6.4.8 Stage
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Technology
      • 5.6.5.4 Application
      • 5.6.5.5 End User
      • 5.6.5.6 Process
      • 5.6.5.7 Mode
      • 5.6.5.8 Stage

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Roche
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Merck
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Bristol Myers Squibb
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Novartis
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Pfizer
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 AstraZeneca
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Johnson and Johnson
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Gilead Sciences
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Amgen
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Sanofi
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Eli Lilly and Company
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 AbbVie
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 GlaxoSmithKline
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Regeneron Pharmaceuticals
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Biogen
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Takeda Pharmaceutical
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Bayer
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Astellas Pharma
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Daiichi Sankyo
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Moderna
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us